N/A N=56 Examining Cooking as a Health Behavior
Obesity
Primary: Weight Change — 7.34; 4.49 kilogram — p=.003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: SAD Part: Number of Subjects Who Experienced Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 4 Participants
Phase 3 N=63 A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
Epilepsy
Primary: Change From Baseline in Weight Z-score up to Month 1 — -0.112; -0.014 Z-score
Phase 2 N=203 Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
Active Psoriatic Arthritis
Primary: Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16 — 31.8; 52.9; 62.7 Percent of Participants — p=<0.001
Phase 2 N=544 COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
Modified Release Oral Formulation · Left Ventricular Systolic Dysfunction · Chronic Heart Failure
Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL
Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer
Phase 1 N=12 Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 5; 3; 3 Participants
Phase 3 N=325 Evaluation of Efficacy and Safety of SDN-037
Inflammation and Pain Associated With Ocular Surgery
Primary: Subjects With an Anterior Chamber Cell Grade of 0 at Day 15 — 96; 30 Participants — p=<.0001
Phase 3 N=130 A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
Allergic Conjunctivitis
Primary: Ocular Itching — 0.81; 0.79; 1.98; 1.09 score on a scale
Phase 2 N=34 Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Stage IIIA Non-small Cell Lung Cancer
Primary: Number of Participants Deemed Feasible to Receive Intervention — 21 Participants
Phase 3 N=75 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
Cancer of the Cervix
Primary: Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle — 49.8; 39.7 percentage of participants
N/A N=28 Clinical Efficacy of Cryolipolysis on the Fat of Thigh in Korean Women
Lipolysis · Cryotherapy Effect
Primary: Change in Cross Sectional Area of Fat in Both Thighs — -420.25; -28.53 millimeters squares
N/A N=80 Perioperative Accuracy of the Raiing Wireless Axillary Thermometer
Major Surgery Under General Anesthesia
Primary: Accuracy of iThermonitor in Surgical Patients — 0.14 celsius — p=<0.05
N/A N=30 rTMS for the Treatment of Freezing of Gait in Parkinson's Disease
Parkinson's Disease
Primary: Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score — -1.60; -2.13 score on a scale
Phase 2 N=3 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Malignant Adrenal Gland Pheochromocytoma · Malignant Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma
Primary: Confirmed Tumor Response Rate — 1.0 participants